AI Article Synopsis

  • Long noncoding RNAs (lncRNAs) TCAM1P-004 and RP11-598D14.1 are often downregulated in hepatocellular carcinoma (HCC) and function as tumor suppressors.
  • Their repression is caused by the histone methyltransferase EZH2, which modifies their promoters and restricts their expression.
  • The loss of these lncRNAs disrupts critical protein interactions that normally regulate essential pathways, promoting cancer cell growth and HCC development, indicating EZH2 as a potential therapeutic target.

Article Abstract

Long noncoding RNAs (lncRNA) play critical roles in the development of cancer, including hepatocellular carcinoma (HCC). However, the mechanisms underlying their deregulation remain largely unexplored. In this study, we report that two lncRNAs frequently downregulated in HCC function as tumor suppressors and are epigenetically silenced by histone methyltransferase EZH2. lncRNAs TCAM1P-004 and RP11-598D14.1 were inhibited by EZH-mediated trimethylation of H3K27me3 at their promoters. Downregulation of TCAM1P-004 and RP11-598D14.1 was frequently observed in HCC tumors compared with adjacent normal tissues. Both lncRNAs inhibited cell growth, cell survival, and transformation in HCC cells as well as tumor formation . Using RNA pull-down and mass spectrometry, we demonstrated that TCAM1P-004 bound IGF2BP1 and HIST1H1C, whereas RP11-598D14.1 bound IGF2BP1 and STAU1. These lncRNA-protein interactions were critical in regulating p53, MAPK, and HIF1α pathways that promoted cell proliferation in HCC. Overexpression of EZH2 was critical in repressing TCAM1P-004 and RP11-598D14.1, and EZH2-TCAM1P-004/RP11-598D14.1-regulated pathways were prevalent in human HCC. Aberrant suppression of TCAM1P-004 and RP11-598D14.1 led to loss of their tumor-suppressive effects by disrupting the interaction with IGF2BP1, HIST1H1C, and STAU1, which in turn promoted HCC development and progression. Collectively, these findings demonstrate the role of TCAMP1P-004 and RP11-598D14.1 in suppressing tumor growth and suggest that EZH2 may serve as a therapeutic target in HCC. SIGNIFICANCE: EZH2-mediated loss of lncRNAs TCAM1P-004 and RP11-598D14.1 hinders the formation of tumor suppressor lncRNA-protein complexes and subsequently promotes HCC growth.

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-18-1659DOI Listing

Publication Analysis

Top Keywords

tcam1p-004 rp11-598d141
20
hcc
9
tumor suppressor
8
long noncoding
8
noncoding rnas
8
epigenetically silenced
8
hepatocellular carcinoma
8
lncrnas tcam1p-004
8
bound igf2bp1
8
igf2bp1 hist1h1c
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!